Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Clinical Cancer Research.
Times cited: 92
T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling.
Times cited: 42